Clinical Trials Logo

Malignant Solid Tumor clinical trials

View clinical trials related to Malignant Solid Tumor.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03192345 Terminated - Clinical trials for Malignant Solid Tumor

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Start date: June 9, 2017
Phase: Phase 1
Study type: Interventional

Primary Objectives: Dose escalation (Part 1) Part 1A (SAR439459 monotherapy) - To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with advanced solid tumors. Part 1B (SAR439459 and cemiplimab combination therapy) - To determine the MTD and/or MAD of SAR439459 administered intravenously in combination with cemiplimab administered intravenously in adult patients with advanced solid tumors. Dose expansion (Part 2) Part 2A (SAR439459 monotherapy) - To determine optimal dose of SAR439459 administered intravenously in adult patients with advanced melanoma who have failed a prior therapy based on anti-PD-1 (programmed cell death-1) or anti-PD-L1. Part 2B (SAR439459 and cemiplimab combination therapy) - To determine the objective response rate (ORR) of SAR439459 in combination with cemiplimab in adult patients with selected advanced solid tumors by evaluation of antitumor response according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). Secondary Objectives: - Pharmacokinetic (PK) profile SAR439459 monotherapy and combined with cemiplimab, PK profile of cemiplimab combined with SAR439459. - Immunogenicity of SAR439459 monotherapy and combined with cemiplimab. Dose escalation (Part 1) - Overall safety/tolerability profile of SAR439459 monotherapy and combined with cemiplimab. - Preliminary recommended phase 2 dose (pRP2D) of SAR439459 as monotherapy or combined with cemiplimab. Dose expansion (Part 2) - Progression free survival (PFS), time to progression (TTP), ORR, and safety of SAR439459 as monotherapy and PFS, TTP, duration of response (DOR), disease control rate (DCR) and safety in combination with cemiplimab. - To confirm the optimal dose of SAR439459 administered in combination with cemiplimab.

NCT ID: NCT02801097 Terminated - Metastatic Cancer Clinical Trials

RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

PAYLOAD
Start date: August 30, 2016
Phase: Phase 1
Study type: Interventional

This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical activity of RRx-001 administered in combination with irinotecan. RRx-001 is associated with resensitization to irinotecan in tumors that are previously refractory. This effect has been attributed to the ability of RRx-001 to restore the expression of aberrantly silenced genes, thus re-establishing pathway functions. However, resensitization may have more than one mechanism, among them Pgp pump inhibition and vascular modulation, leading to improved penetration of standard chemotherapy.

NCT ID: NCT02096341 Terminated - Lymphomas Clinical Trials

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

Start date: April 2014
Phase: Phase 1
Study type: Interventional

To investigate the dosage of RRx-001 by the subcutaneous route.

NCT ID: NCT01846429 Terminated - Pain Clinical Trials

Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain

Start date: September 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to: - Determine how well people tolerate sodium bicarbonate taken by mouth in higher doses than those usually given for heartburn. - Determine if sodium bicarbonate can reduce cancer-related pain.

NCT ID: NCT01632696 Terminated - Clinical trials for Malignant Solid Tumor

Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors

Start date: June 2012
Phase: Early Phase 1
Study type: Interventional

Tumor Imaging of I-124 PGN65 in Solid Tumors